PMID- 16040385
OWN - NLM
STAT- MEDLINE
DCOM- 20050825
LR  - 20171116
IS  - 1465-3249 (Print)
IS  - 1465-3249 (Linking)
VI  - 7
IP  - 1
DP  - 2005
TI  - B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows 
      the generation of large numbers of efficient xenoantigen-free APC.
PG  - 62-73
AB  - BACKGROUND: CD40-activated B lymphocytes have been used successfully as potent 
      APC for the induction of T-cell responses. However, the 3T3-CD40L cell line, 
      regularly used for engagement of CD40 on the B-cell surface, is a potential 
      source of xenoantigens. This may affect the specificity of T cells stimulated 
      with CD40-activated B cells, especially when generation of T-cell lines specific 
      for endogenously processed Ag is desired. METHODS: To develop a system that 
      allows efficient expansion of B cells in the absence of sources of xenoantigens, 
      we created a human 293-CD40L-sCD40L cell line that produces soluble CD40L and 
      expresses CD40L on the cell surface. B cells from patients with hematologic 
      malignancies were expanded on the 293-CD40L-sCD40L cells and used for stimulation 
      of either naive or in vivo primed donor T cells in three HLA-identical 
      patient-donor combinations. RESULTS: The 293-CD40L-sCD40L cell line was able to 
      stimulate B-cell growth with an efficiency superior to that of the commonly used 
      3T3-CD40L cell line. In all cases T-cell lines and, subsequently, T-cell clones 
      were generated that showed reactivity against patient and not donor B cells, 
      suggesting their specificity for minor histocompatibility antigens (mHAg). 
      DISCUSSION: B cells activated with GMP grade 293-CD40L-sCD40L can be used in a 
      variety of applications. In particular, they may be suitable for ex vivo 
      stimulation of T cells prior to donor lymphocyte infusion (DLI), which may 
      enhance its graft versus leukemia (GvL) effect.
FAU - Ivanov, R
AU  - Ivanov R
AD  - Jordan Laboratory for Hemato-Oncology, Department of Hematology, University 
      Medical Center Utrecht, The Netherlands.
FAU - Aarts, T
AU  - Aarts T
FAU - Hagenbeek, A
AU  - Hagenbeek A
FAU - Hol, S
AU  - Hol S
FAU - Ebeling, S
AU  - Ebeling S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Antigens, Heterophile)
RN  - 0 (CD40 Antigens)
RN  - 0 (HLA Antigens)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - 3T3 Cells/immunology
MH  - Animals
MH  - Antigen-Presenting Cells/*cytology/immunology
MH  - Antigens, Heterophile/immunology
MH  - B-Lymphocytes/*immunology/transplantation
MH  - CD40 Antigens/immunology
MH  - CD40 Ligand/*biosynthesis/immunology
MH  - Cell Culture Techniques/methods
MH  - Cell Differentiation/immunology
MH  - *Cell Line
MH  - Cell Proliferation
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Leukemia/immunology/therapy
MH  - Lymphocyte Activation/*immunology
MH  - Lymphocyte Transfusion/methods
MH  - Mice
MH  - Minor Histocompatibility Antigens/immunology
MH  - Solubility
MH  - T-Lymphocytes/immunology
EDAT- 2005/07/26 09:00
MHDA- 2005/08/27 09:00
CRDT- 2005/07/26 09:00
PHST- 2005/07/26 09:00 [pubmed]
PHST- 2005/08/27 09:00 [medline]
PHST- 2005/07/26 09:00 [entrez]
AID - GJ4C49FANTFDP91H [pii]
AID - 10.1080/14653240510018055 [doi]
PST - ppublish
SO  - Cytotherapy. 2005;7(1):62-73. doi: 10.1080/14653240510018055.